<DOC>
	<DOCNO>NCT02039791</DOCNO>
	<brief_summary>Nimotuzumab humanize monoclonal antibody epidermal growth factor receptor ( EGFR ) . Clinical trial ongoing globally evaluate Nimotuzumab different indication . Nimotuzumab approve treat squamous cell carcinoma head neck ( SCCHN ) , glioma nasopharyngeal carcinoma different country . The clinical phaseⅡtrial design assess resection rate pathological complete response nimotuzumab plus carboplatin paclitaxel patient cervical cancer .</brief_summary>
	<brief_title>Study Nimotuzumab Combination With Neoadjuvant Chemotherapy Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Age:1870 year 2 . Histological confirm Cervical squamous cell carcinoma 3 . FIGO Stage : IB2IIIB 4 . Tumor lesion stage confirm internal medicine , obstetrics gynecology inspection , include pelvic exam abdominal pelvic CT , .if necessary , laparoscopy , cystoscopy pelvic MRI examination take . 5 . At least one lesion measure 6 . No previous therapy 7 . ECOG performance status 02 8 . Life expectancy 6 month 9 . Normal hematology : Haemoglobin≥90g/L , white blood cell ( WBC ) ≥4×109/L Absolute neutrophil count≥1.5×109/L , platelet count≥100×109/L , normal renal function : serum creatinine &lt; 1.5mg/dl creatinine clearance rate &gt; 60ml/min；normal liver function : TBIL≤1.5 ULN , AST ALT≤1.5 ULN 10 . Without lung heart disease 11 . Without active infection 12 . Signed informed consent submit organization research 1 . Severe systemic uncontrolled disease , unfit chemotherapy 2 . Neuropathy cause reason 3 . Psychiatric disease 4 . Other malignant tumor 5 . Bilateral renal pelvis ureter hydrocephalus ca n't alleviate ureteral stent percutaneous nephrostomy , Abnormal serum creatinine level 6 . Infection severe systemic disease 7 . Received anti EGFR monoclonal antibody treatment 8 . Participation interventional clinical trial 9 . Allergic constitution history drug allergy 10 . Pregnant breastfeeding refuse take contraceptive method 11 . Poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>